000177487 001__ 177487
000177487 005__ 20240229133741.0
000177487 037__ $$aDKFZ-2021-02574
000177487 1001_ $$0P:(DE-HGF)0$$aMansour, P.$$b0
000177487 245__ $$aGeneration of CAR-T cells using lentiviral vectors
000177487 260__ $$aUnited States$$bAcademic Press Inc.$$c2021
000177487 29510 $$aMethods in Cell Biology
000177487 300__ $$a-
000177487 3367_ $$2ORCID$$aBOOK_CHAPTER
000177487 3367_ $$07$$2EndNote$$aBook Section
000177487 3367_ $$2DRIVER$$abookPart
000177487 3367_ $$2BibTeX$$aINBOOK
000177487 3367_ $$2DataCite$$aOutput Types/Book chapter
000177487 3367_ $$0PUB:(DE-HGF)7$$2PUB:(DE-HGF)$$aContribution to a book$$bcontb$$mcontb$$s1637231604_29975
000177487 520__ $$aCancer immunotherapy is nowadays largely focused on the development of therapeutic antibodies and chimeric antigen receptors (CARs). Two CARs targeting CD19 have been approved recently for the treatment of some hematological malignancies. This demonstrates the capability of engineered CAR T cells in generating effective tumor responses. Furthermore, several hundred ongoing clinical trials are exploring the feasibility of CAR-based approaches to target tumor-associated antigens in solid tumors. However, there still remain significant challenges and limitations in the design and production of CAR-modified T cells that need to be addressed, such as more effective transduction methods, expression and exhaustion issues, reliable in vitro and in vivo characterization methods, etc. Here we describe current techniques for generating CAR T cells using lentiviral vectors as well as detailed protocols for their functional characterization.https://reader.elsevier.com/reader/sd/pii/S0091679X21000844?token=19B8578AB0A842C9E0A423517A3E8821C298512484E57C501C77B440E558856281E370B178DDAB9F208EBEE22E875043&originRegion=eu-west-1&originCreation=20211118072303
000177487 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000177487 7001_ $$0P:(DE-He78)987b26d1b6cb44a440dac6d4342fc8d2$$aQuiros Fernandez, Isaac$$b1$$udkfz
000177487 7001_ $$0P:(DE-He78)148613c9c06b4ac0e307b6fa7787fc9d$$aFakhr, Elham$$b2$$udkfz
000177487 7001_ $$0P:(DE-He78)a30064f6b2d9ab959d35315d7668c091$$aCid-Arregui, Angel$$b3$$udkfz
000177487 909CO $$ooai:inrepo02.dkfz.de:177487$$pVDB
000177487 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000177487 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)987b26d1b6cb44a440dac6d4342fc8d2$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000177487 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)148613c9c06b4ac0e307b6fa7787fc9d$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000177487 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a30064f6b2d9ab959d35315d7668c091$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000177487 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000177487 9141_ $$y2021
000177487 9201_ $$0I:(DE-He78)D122-20160331$$kD122$$lD122 AG Gezielte Tumorvakzine$$x0
000177487 980__ $$acontb
000177487 980__ $$aVDB
000177487 980__ $$aI:(DE-He78)D122-20160331
000177487 980__ $$aUNRESTRICTED